REGENTIS BIOMATERIALS LTD/IS
RGNTNYSE AMERICANTrading Snapshot
- Day Range
- $1.83 – $1.86
- 52-Week Range
- $1.23 – $15.50
- Volume
- $1.89B
- Avg Volume
- $1.96B
- Shares Outstanding
- 7.0M
- Next Earnings
- Sep 14, 2026
Fundamentals Snapshot
- Annual Revenue
- $2M
- Last Q Revenue
- $661,913
- P/E Ratio
- —
- P/S Ratio
- —
- EPS (TTM)
- —
- Dividend Yield
- —
Why Investors Own RGNT
- ✓High-growth profile — revenue up +33.0% YoY with expanding US Equity exposure.
- ✓Healthy economics — 38% gross margin and 19% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About REGENTIS BIOMATERIALS LTD/IS
Regentis Biomaterials Ltd. is a regenerative medicine firm dedicated to crafting innovative solutions for tissue repair, ultimately aiming to enhance patients' health and overall quality of life. The company's primary product in development is GelrinC, a novel, cell-free, ready-to-use hydrogel designed to be solidified into an implant within the knee. This implant serves to address painful knee injuries and mend articular cartilage damage. Regentis Biomaterials leverages its proprietary Gelrin platform, which employs biodegradable hydrogel implants, to develop orthopedic therapies that facilitate the regeneration of compromised or diseased tissues. The company was established in 2004 and operates from its headquarters in Herzliya, Israel.
Otter Score Breakdown
ⓘAnalyst Price Target
ⓘLatest News & Updates
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Autonomix Medical (NASDAQ:AMIX) stock rose 49.1% to $4.1 during Tuesday's after-market session. The market value of their outstanding shares is at $1.5 million. CalciMedica (NASDAQ:CALC) shares rose 9.8%
Regentis Gets Japan Patent Office Notice of Allowance For Organic Solvent‑Free Protein‑Polymer Conjugate Compositions, Covering GelrinC Manufacturing Process And Ready‑to‑Use Liquid Formulation for Articular Cartilage Repair
Patent expands intellectual property protection in one of the world's largest cartilage repair marketsGelrinC is a cell-free hydrogel delivered in a single ~10-minute procedure eliminating the need for cell
Regentis Biomaterials Receives European Regulatory Approval For New GelrinC Manufacturing Process
The approval comes as Regentis prepares for the commercial launch of GelrinC® in Europe, enabling the Company to manufacture commercial product using a process that increases production yield by approximately 400%,
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers NextCure (NASDAQ:NXTC) stock increased by 201.4% to $6.57 during Tuesday's regular session. The market value of their outstanding shares is at $7.8 million. Shuttle Pharmaceuticals (NASDAQ:SHPH) shares